Coherus BioSciences Priced, Nasdaq: CHRS

Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.

Industry: Health Care

Latest Trade: $20.70 0.00 (0.0%)

First Day Return: -6.6%

Return from IPO: +53.3%

Industry: Health Care

Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.
more less
IPO News for Coherus BioSciences
more
IPO Data
IPO File Date 09/25/2014
Offer Price $13.50
Price Range $12.00 - $15.00
Offer Shares (mm) 6.3
Deal Size ($mm) $85
IPO Data
IPO Date 11/06/2014
Offer Price $13.50
Price Range $12.00 - $15.00
Offer Shares (mm) 6.3
Deal Size ($mm) $85
Underwriters
more
Company Data
Headquarters Redwood City, CA
Founded 2010
Employees 46
Website www.coherus.com